Where Does Arena Pharmaceuticals, Inc. (ARNA) Stock Fall in the Biotechnology Field After It Is Higher By 4.79% This Week?

Thursday, September 09, 2021 02:08 PM | InvestorsObserver Analysts

Mentioned in this article

Where Does Arena Pharmaceuticals, Inc. (ARNA) Stock Fall in the Biotechnology Field After It Is Higher By 4.79% This Week?

The 36 rating InvestorsObserver gives to Arena Pharmaceuticals, Inc. (ARNA) stock puts it near the middle of the Biotechnology industry. In addition to scoring higher than 42 percent of stocks in the Biotechnology industry, ARNA’s 36 overall rating means the stock scores better than 36 percent of all stocks.

ARNA has an Overall Score of 36. Find out what this means to you and get the rest of the rankings on ARNA!

See Full ARNA Report

What do These Ratings Mean?

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. InvestorsObserver allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 36 would rank higher than 36 percent of all stocks. These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

What's Happening With Arena Pharmaceuticals, Inc. Stock Today?

Arena Pharmaceuticals, Inc. (ARNA) stock has gained 0.07% while the S&P 500 is lower by -0.33% as of 2:07 PM on Thursday, Sep 9. ARNA has gained $0.04 from the previous closing price of $59.46 on volume of 247,089 shares. Over the past year the S&P 500 is higher by 32.37% while ARNA is lower by -7.92%. ARNA lost -$8.17 per share the over the last 12 months. Click Here to get the full Stock Report for Arena Pharmaceuticals, Inc. stock.